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Trinucleotide-repeat expansion diseases (TREDs) are a group of inherited human genetic
disorders normally involving late-onset neurological/neurodegenerative affectation.
Trinucleotide-repeat expansions occur in coding and non-coding regions of unique genes
that typically result in protein and RNA toxic gain of function, respectively. In polyglutamine
(polyQ) disorders caused by an expanded CAG repeat in the coding region of speciﬁc
genes, neuronal dysfunction has been traditionally linked to the long polyQ stretch.
However, a number of evidences suggest a detrimental role of the expanded/mutant
mRNA, which may contribute to cell function impairment. In this review we describe the
mechanisms of RNA-induced toxicity inTREDs with special focus in small-non-coding RNA
pathogenic mechanisms and we summarize and comment on translational approaches
targeting the expanded trinucleotide-repeat for disease modifying therapies.
Keywords: small non-coding RNAs, trinucleotide repeat expansion, RNA-toxicity, miRNA, antisense small RNA
INTRODUCTION
In the human genome trinucleotide repeats (TNR) are especially
abundant in intergenic regions, gene introns and untranslated
regions, and translated segments of protein coding genes. Short
tandem-TNRhave generally less than 30 copies in the normal pop-
ulation (Ellegren, 2004). Abnormal expansions of certain types of
TNR result in trinucleotide repeat expansion diseases (TREDs), a
group of inherited human genetic disorders involving the ner-
vous system (Table 1; Orr and Zoghbi, 2007). Expansions of
triplet repeats occur in coding or non-coding regions of unre-
lated genes and typically result in late-onset neurological diseases.
Disease severity and onset are largely dependent on the expansion
length. The pathogenic mechanisms associated to TNR expan-
sions have been an extensive ﬁeld of research over the last two
decades. Different studies have revealed a tremendous complexity
in the pathomechanisms, with diverse detrimental effects proba-
bly coexisting in cells. This complexity lies beneath the selective
affectation of speciﬁc cell types in the brain, which is characteristic
in each TRED.
The largest group of inherited polyglutamine (polyQ) dis-
orders is caused by expansions of CAG repeats in the open
reading frame (ORF) of unique genes, including the Hunting-
ton’s disease (HD) genes and several spinocerebellar ataxias (SCA)
genes. In these diseases the predominant hypothesis has been that
the expanded polyQ track confers detrimental properties to the
protein, that compromise cell homeostasis. The consequences
of polyQ expansion in the HTT protein have been systemat-
ically characterized, with detrimental effects in transcriptional
activity, vesicle trafﬁcking, mitochondrial function and protea-
some activity (Zheng and Diamond, 2012). However, the view of a
protein-based toxocity in polyQ disorders has been challenged, as
recent ﬁndings point to an additional toxic effect of the expanded
CAG in the exon 1 of HTT mRNA (Banez-Coronel et al., 2012).
TNR expansions also occur in non-translated regions of selec-
tive genes. In myotonic dystrophy (DM1) a CTG expansion in the
3′UTR of the DMPK gene (50–3000 repeats) leads to neuromus-
cular degeneration (Brook et al., 1992). A CGG expansion (above
200 repeats) in the 5′-untranslated region (5′UTR) of the FMR1
gene produces fragile X syndrome, themost common type of men-
tal retardation. Yet, shorter CGG expansions (55–200 repeats) are
associated to different pathologies such as fragile X tremor/ataxia
syndrome (FXTAS) and primary ovarian failure (POF; Verkerk
et al., 1991; Hagerman and Hagerman, 2004). Expansions occur-
ring in non-translated regions produce RNAs with a toxic gain
of function, involving a number of mechanisms, described in
subsequent sections.
The recent discovery of repeat associated non-ATG (RAN)
translation (Zu et al., 2011) has changed the view of TREDs patho-
genesis, as toxic proteins may be also produced from expanded
TNR thought to be embedded in non-coding RNAs. RAN-
translation from Ataxin8 Oposite Strand (Ataxin8_OS) with an
expandedCAGhas been shown indifferent frames, in SCA8mouse
models and in patients with SCA8 (Zu et al., 2011). The same
study showed RAN-translation across DM1 transcripts, resulting
in the accumulation of PolyQ expanded proteins in DM1 mice
models myoblasts and cardiomyocites. A similar phenomenon has
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been recently demonstrated in expanded CGG repeats in FMR1
5′-UTR (Todd et al., 2013). A cryptic polyglycine-containing pro-
tein (FMRpolyG) was detected accumulating in ubiquitin-positive
inclusions in Drosophila, cell culture and mouse disease mod-
els, and in brains of patients with FXTAS. The relevance of this
mechanism needs to be speciﬁcally addressed for each TRED.
In this review we focus on the RNA pathogenic mechanisms
in TREDs. We present the existing evidences for RNA binding
protein (RBP) sequestration by different expanded TNR and the
linked altered biological processes. We address the possible rel-
evance of bidirectional transcritption in TREDs loci and further
discuss about the role of small non-coding RNAs in TREDs patho-
genesis. Finally, we summarize the latest therapeutic strategies in
TREDs, based on selective targeting of the allele with the expanded
TNR.
MECHANISMS OF RNA-TOXICITY IN TREDs
Recent ﬁndings indicate that alterations of RNA sequences can
lead to abnormal RNA–protein interactions, alteration of pro-
tein translation, or RNA interference (RNAi) activation, among
other anomalous processes. These altered pathways contribute to
disruption of normal cell function and homeostasis, eventually
leading to cell degeneration.
TRINUCLEOTIDE REPEAT EXPANSIONS MODIFY ALTERNATIVE
SPLICING EVENTS
In TREDs abnormal expanded TNR RNA–protein interactions
results in disrupted protein conformation and inclusion forma-
tion. Sequestration of RBP by the expanded TNR leads to a loss
FIGURE 1 | ExpandedTNR induce altered mRNA splicing inTREDs.
Expanded CNG repeats sequester RBP in the nucleus that modulate exon
usage during pre-mRNA maturation, including MBNL1, CELF1, p68/DDX5,
hnRNP A2/B1, Pur a, Sam68. This results in altered alternative splicing in
several genes, producing misslocalized or dysfunctional proteins that
contribute to pathogenesis in TREDs.
of function of such proteins (Figure 1). Muscleblind-like splicing
regulator 1 (MBNL1) and Elav-like family member 1 (CUGBP1
or CELF1) are regulators of mRNA splicing that present afﬁnity
for CUG and/or CAG repeats. In DM1, long CUG repeats lead to
decreased MBNL1 activity and increased CELF1 activity in muscle
cells, which results in mis-splicing events in different develop-
mentally regulated genes including the insulin receptor (IR), the
chloride channel (CLCN1) and the cardiac tropin T (TNNT2),
which explain several aspects of DM1 symptomatology (Ranum
and Cooper, 2006; Wheeler and Thornton, 2007).
Aberrant splicing of the bridging integrator-1 (BIN1) pre-
mRNA has been recently described in DM1 (Fugier et al., 2011).
BIN1 protein is required for the biogenesis of muscle T tubules,
essential for excitation-contraction coupling. Mis-splicing of BIN1
linked to a loss of function of MBNL1, produces an inactive form
of BIN1 protein. While direct interaction of MBNL1 with the
CUG repeat depletes MBNL1, increased levels of CEFL1 are the
consequence of an indirect effect of CUG expansion involving
PKC-pathways (Kuyumcu-Martinez et al., 2007). CELF1 hyper-
phosphorylation mediated by PKC, leads to its increased stability
and activity (Kuyumcu-Martinez et al., 2007). Splicing alterations
have been also reported in DM1 and SCA8 brains, with neu-
ronal cells showing MBNL1 nuclear inclusions (Jiang et al., 2004;
Daughters et al., 2009; Mykowska et al., 2011). Abnormal splicing
of multiple exons in microtubule associated protein tau (MAPT),
and exon 7 in the amyloid precursor protein (APP) and exon 5
in glutamate receptor NMDAR1, have been detected in brains of
DM1patients andmousemodels (Jiang et al., 2004; Gomes-Pereira
et al., 2007) and analogous splicing alterations have been shown
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in SCA8 mice (Daughters et al., 2009) which may explain neuro-
logical alterations in these diseases. The relevance of expanded
RNA-MBNL1 interaction in DM1 is strengthened in a mouse
model expressing an expanded CUG RNA that recapitulates DM1
phenotypes. In this model, partial recovery of the mis-splicing
defects is achieved by reestablishing MBNL1 levels. Another
recently described repeated-CUG interactor is the p68/DDX5heli-
case, which is present in mutant DMPK foci in DM1 (Laurent
et al., 2012). p68/DDX5 modiﬁes of MBNL1 splicing activity and
has been proposed to inﬂuence pathogenicity in DM1.
The CGG expansions in the FMR1 5′UTR causing FXTAS may
also sequester MBNL1, which is accumulated as abnormal inclu-
sions in brain of FXTAS patients (Iwahashi et al., 2006). Other
RBPs with speciﬁc afﬁnity for CGG repeats are Pur-α and hnRNP
A2/B1, which have been found in inclusions in FXTAS models
(Jin et al., 2007; Sofola et al., 2007). In addition, CELF1 indirect
binding to the CGG repeats through the RBP hnRNP A2/B1, leads
to its loss of function (Sofola et al., 2007). Loss of function of
Pur-α and hnRNP A2/B1 induce neurological alterations in mice
(Khalili et al., 2003), suggesting their participation in FXTAS neu-
ropathology. Recently, loss of function of the splicing factor Sam68
through binding to expanded CGG repeats has been shown in
FXTAS patients, contributing to aberrant splicing of the ATPase
ATP11B and the Survival of Motor Neuron 2, centomeric SMN2
genes (Sellier et al., 2010).
FIGURE 2 | Altered miRNA biogenesis inTREDs. Expanded CNG repeats
have afﬁnity for key players of miRNA biogenesis such as DROSHA and
DGCR8. Other proteins modulating the activity of DROSHA complex, such as
MBNL1, p72 and p68, are also sequestered by expandedTNR. Functional
depletion of these proteins leads to decreased production of mature miRNAs,
which results in increased expression of miRNA targets.
Together, these data indicate that loss of function of RBP that
have afﬁnity for expanded TNR is a common mechanism oper-
ating in TREDS and further suggest that full characterization of
the set of RBP binding to different types of TNR expansions will
provide insights into speciﬁc pathogenic processes.
TRINUCLEOTIDE-REPEAT EXPANSIONS ALTER miRNA BIOGENESIS
The most recent ﬁndings suggest that sequestration of RBP by
TNR expansions has other consequences in addition to alternative
splicing perturbations (Figure 2). MBNL1 and the RNA heli-
cases p68 and p72 inﬂuence the activity of proteins involved in
microRNA (miRNA) biogenesis (Fukuda et al., 2007; Rau et al.,
2011). MBNL1 in normal conditions binds to pre-miR-1 precur-
sor, allowing the normal production of mature miR-1. Depletion
of MBNL1 in DM1 permits the activity of the processing regulator
LIN28, which binds to pre-miR-1 and promotes 3′-end uridy-
lation, thus resulting in inhibition of pre-miR-1 processing by
the endonuclease Dicer. The disruption of the normal pre-miR-1
processing by MBNL1 loss of function results in increased levels
of miR-1 targets, including the calcium channel CACNA1C and
the gap-junction channel GJA1, which may contribute to the car-
diac defects in DM1 (Rau et al., 2011). The modulatory role of
p68 and p72 helicases in the miRNA-processing complex (Fukuda
et al., 2007) suggest that analogousmechanismsmay exist for these
proteins.
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Alterations in miRNA biogenesis pathways have been also
described in FXTAS (Sellier et al., 2013). The hairpin structure
of the expanded CGG in the FMR1 5′UTR mRNA mimics the
structure of the miRNA-precursors (pri-miRNAs). DGCR8 and
its partner DROSHA, key players in miRNA-precursor process-
ing, are sequestered by CGG-RNA repeats (Figure 2). Depletion
of these processors compromises the biogenesis of many miRNAs,
thus triggering downstream detrimental gene expression pertur-
bations, which likely contribute to FXTAS pathogenesis. However,
this mechanism may be tissue-dependent, as small RNA proﬁling
in peripheral blood of FXTAS patients does not reveal a general
miRNA downregulation (Alvarez-Mora et al., 2013).
General perturbations in miRNA biogenesis result in altered
mature miRNAs expression and subsequent modiﬁcations of gene
silencing, which likely contribute to disrupted cell homeostasis in
TREDs.
BIOGENESIS AND ACTIVITY OF SMALL REPEATED CNG IN TREDs
SENSE TRANSCRIPTS
The hairpin structure of expandedCNG repeats (Galka-Marciniak
et al., 2012) constitutes a substrate for Dicer, an endonuclease
involved in miRNA biogenesis that excises RNA precursors to
generate the mature short miRNA (Figure 3). Dicer recognizes
the expanded triplet and cleaves it, producing small repeated
RNAs (sCNG). In vitro approaches demonstrated that single
stranded CGG-RNA constructs are cleaved by Dicer, producing
short CGG-RNAs of approximately 21 nt (sCGG; Handa et al.,
2003). Recombinant Dicer also cleaves long transcripts contain-
ing other types of long CNG repeats (CAG,CUG,CCG; Krol et al.,
2007). Importantly, theDicer-dependence of sCNGbiogenesis has
been demonstrated in ﬁbroblasts of patients with DM1 (sCUG),
HD (sCAG) and SCA1 (sCAG; Krol et al., 2007). In this study the
authors further showed that sCNG were active as transcriptional
inhibitors, since they downregulated the expression of transcripts
with complementary target sequences. This inhibitory activity was
dependent onAgo2, a keymember of theRNAsilencingmachinery
(Krol et al., 2007).
The relevance of sCNG in TREDs pathogenesis has been
recently addressed in HD (Banez-Coronel et al., 2012). This study
conﬁrmed the biogenesis of sCAG in a neuronal cell model
expressing expanded HTT exon-1, and in brain samples of
patients with HD or the R6/2 HD mouse model. Importantly,
the fraction of small RNAs (sRNAs) derived from cells expressing
expanded HTT exon-1 produced neuronal death. Both the bio-
genesis and the toxic activity of sCAG were dependent on Dicer.
Similarly, transfection of sRNAs isolated from the striatum and
cortex of patients with HD induced signiﬁcant neuronal toxicity.
This toxic effect was prevented by oligonucleotides complemen-
tary to short CAG, strongly suggesting a detrimental effect of
sCAG. Furthermore, toxicity may depend on downstream silenc-
ing effects, as HTT exon-1-derived sCAG were loaded onto Ago2
complexes and knocking-down of Ago2 prevented damage. How-
ever, the sequence/structure requirements for effective silencing
of sCAG-targets remain to be resolved, since similar moderate
inhibition was detected in luciferase assays performed with targets
harboring a perfect sCAG-complementary CTG repeat or a CAG
repeat that offers an interrupted sCAG target site. Whether the
detrimental properties of sCAG include silencing effect through
mRNA degradation and/or translational repression, or perturb
gene expression networks through other mechanisms, remains to
be determined. Interestingly, this study shows that the effect of
sCAG-RNAs differed depending on the cell type, with high toxi-
city detected in BDNF-differentiated neuroblastoma cells. In this
scenario, sCAG activity may provide a mechanism contributing to
tissue selective affectation. The relevance of sCNG biogenesis and
activity in other TREDs is an interesting ﬁeld for future studies.
BIDIRECTIONAL TRANSCRIPTION IN TREDs LOCI PRODUCE NEW
PATHOGENIC PLAYERS
Much of the transcriptome is transcribed in both directions
(Chen et al., 2004). While recent data suggest that only a small
part of the sense transcript produces proteins (Derrien et al.,
2012), the anti-sense transcripts, normally less abundant, are
involved in the regulation of gene expression (He et al., 2008; Mor-
ris et al., 2008; Yu et al., 2008; Batra et al., 2010). Bidirectional
transcription has been detected in many TREDs loci includ-
ing, DM1, SCA8, FXTAS, SCA7, HDL2, and HD, suggesting
a role in disease pathogenesis (Table 1; Cho et al., 2005; Ladd
et al., 2007; Batra et al., 2010; Chung et al., 2011; Sopher et al.,
2011; Wilburn et al., 2011; Seixas et al., 2012). Thus, TREDs
pathogenic mechanisms typically associated with expanded toxic
RNA may be complemented with those induced by abnormal
expanded peptides that result from coding-antisense transcripts
or by a complementary non-coding expanded RNA. For instance,
in SCA8, the progressive cerebellar degeneration inducing ataxia
is the consequence of a CUG expansion in the 3’ end of the
non-protein coding Ataxin 8OS mRNA (Koob et al., 1999; Day
et al., 2000). This led to the conclusion that the pathogenic mech-
anism was related with an expanded CUG-RNA toxic gain of
function. Subsequently, bidirectional transcription was demon-
strated in transgenic mice expressing the entire human locus
with either normal or expanded CTG allele (Moseley et al., 2006).
A progressive neuronal loss was found in the lines expressing
expanded CUG, with concomitant co-expression of two tran-
scripts in opposite directions. The sense transcript produced a
non-coding CUG-expanded transcript (Ataxin 8OS) and an anti-
sense transcript resulted in a CAG expansion that was translated
into a highly enriched polyQ track (Ataxin 8). Intranuclear inclu-
sions immunopositive for anti-polyQ antibodies, which are typical
from PolyQ diseases and CUG foci formation co-localizing with
MNBL1 were detected in cerebellar cells of the mouse model
and patients with SCA8 (Daughters et al., 2009). Thus, both
RNA and protein toxic gain of function may account for SCA8
pathogenesis.
A similar process could account for HDL2 pathogenesis that
is caused by a CUG/CAG repeat expansion at the Juctophilin-3
(JPH3) locus (Holmes et al., 2001), The alternatively spliced forms
in the JPH3 gene place the CUG expansion in the polyleucine
or polyalanine ORFs or in the 3′UTR. A JPH3 transcript with
expanded CUG repeats produce RNA foci that co-localize with
MNBL1 and induces cell toxicity (Rudnicki et al., 2007). The exis-
tence of an anti-sense CAG transcript in the JPH3 locus was
recently demonstrated, which may account for the detected polyQ
proteianceous inclusions (Wilburn et al., 2011).
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FIGURE 3 | Biogenesis and activity of sCNG in TREDs. TNR
expansions produce hairpin-like structures that are recognized and
cleaved by Dicer to form small RNAs with repeated TNR (sCNG).
Bidirectional transcription though the expanded TNR offers another
source of sCNG, where perfectly complementary double stranded
mRNAs with expanded TNR are cleaved by Dicer to form sCNG. sCNG
are incorporated into the RISC complex and silence genes with partial or
perfect complementarity.
Anti-sense transcripts spanning the CGG repeat have been
described in the FMR1 locus (FMR1AS) in human lymphoblas-
toma cells (Ladd et al., 2007). FMR1AS is spliced, processed and
exported from the nucleus. The regulation of FMR1AS expres-
sion is dependent on CGG expansion size; being silenced in full
CGG mutations (CGG> 200 nt), similar to the FMR1 sense tran-
script. A recent study suggested that elevated expression levels of
the sense and antisense expanded FMR1 involving mitochondrial
dysfunction participate in parkinsonism phenotype that is associ-
ated with CGG-repeat moderate expansions (Loesch et al., 2011).
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Thus, both FMR1 and ASFMR1 may contribute to the variable
phenotypes associated with the CGG repeat expansion.
Anti-sense transcription at the DM1 locus has also been
reported (Cho et al., 2005). Both sense and antisense transcripts
extending across the CAG repeat were found in independent
nuclear foci in a mouse model carrying >1,000 CTG repeats in
the DM1 locus and in human tissues (Huguet et al., 2012).
HTT anti-sense (HTTAS) transcripts have been identiﬁed that
contain the repeated CAG track (Chung et al., 2011). Repeat
expansion reduces HTTAS promoter efﬁciency, and therefore
HTTAS expression is reduced in the brain of HDpatients. Through
knocking down the HTTAS transcript the authors demonstrated
its regulatory activity on HTT expression. The relevance of this
regulatory mechanism in HD has not been addressed. However,
a possibility exists that HTTAS provides an expanded CUG-based
pathogenic mechanism.
One interesting mechanism derived from anti-sense transcrip-
tion of genes containing TNR expansions is the activation of
silencing mechanisms (Figure 3). Complementary repeats can
form double-stranded structures compatible with endonuclease
Dicer slicing activity. This results in the formation of short
repeated RNAs that are incorporated into the RISC complex,
possibly driving downstream gene silencing with detrimental con-
sequences. This mechanism has been proven in a DM1 Drosophila
model, in which the toxic effect of an expanded CUG track was
largely enhanced if co-expressed with a CAG expansion. The
co-expression of sense and anti-sense transcripts lead to the for-
mation of repeat-derived small interfering RNAs in a process
dependent of Dicer-2 and Ago-2 (Yu et al., 2011). Similarly, ﬂies
models expressing CAG/CUG -100 nt double stranded RNAs
(Lawlor et al., 2011) showed a Dicer 2-dependent progressive
neurodegenerative phenotype.
From these results it seems clear that small double stranded
RNAs are detrimental for neuronal cells. However, the relevance of
bidirectional transcription derived-siRNA in human disease needs
to be proven, as the expression of antisense transcripts is normally
low, which may limit the formation of these products.
In summary, bidirectional transcription through repeat regions
of TREDs genes likely increases the complexity of the pathogenic
mechanisms underlying the disease process, including the seques-
tration of different RBP and the biogenesis of small repeated TNR
RNAs with silencing activity.
EVIDENCES FOR RNA TOXICITY IN POLYQ DISORDERS
Although in polyQ diseases pathogenesis has been traditionally
linked to altered function of the protein, a number of evidences
suggest a complementary detrimental role of the expanded RNA.
In vitro structure determinations of expanded CAG repeats in
the mRNA context of the HTT, ATXN1-3, ATN1 and AR genes
that cause different polyQ diseases (Table 1) show compatibil-
ity with double stranded hairpin formation (Galka-Marciniak
et al., 2012). Biochemical studies further suggested that MBNL1
has similar afﬁnity for RNA containing either CUG or CAG
repeats (Yuan et al., 2007). Although CAG expansions in polyQ
diseases occur in the protein coding sequence, nuclear RNA
inclusions accumulating MBNL1 have been detected in ﬁbrob-
lasts of patients with ATXN3 and HD (de Mezer et al., 2011;
Mykowska et al., 2011). Alternative splicing defects similar to
those observed in DM1 have been shown in these cells, suggest-
ing that splicing alterations are likely the consequence of MBNL1
sequestration.
Expanded CAG repeats were shown to induce in vivo toxicity
at the RNA level in Drosophila, C. elegans and mouse models.
The in vivo evidence for repeated CAG RNA toxicity was ﬁrst
obtained in a Drosophila model of SCA3 (Li et al., 2008). The
expression of untranslatedCAGrepeats of pathogenic length led to
neurodegeneration in the absence of a mutant polyQ protein. The
expression of translated CAA or interrupted CAG repeats resulted
in a less severe phenotype than the expression of translated pure
CAG repeats, which supported the importance of RNA structure
for toxicity.
TheCAGrepeat toxicity at theRNA levelwas also demonstrated
in a worm system (Wang et al., 2011). Both CAG and CUG repeats
of pathological length were shown to form nuclear foci, in which
the mutant transcript colocalized with the nematode ortholog of
MBNL1, CeMBL. The disease phenotype was partially reversed by
CeMBL over-expression.
The expression of untranslated long CAG repeats (200 copies)
was also shown to be deleterious in transgenic mice (Hsu
et al., 2011). Mice expressing EGFP transcripts with long CAG
repeats in the 3′-UTR developed electrophysiological, histological
and behavioral aberrations in the muscle. Detection of nuclear
RNA foci in muscle cells in this model (Hsu et al., 2011) and
in the striatum of the YAC128 HD mouse model expressing
full-length human HTT (Pouladi et al., 2012) further suggests
toxicity through expanded CAG-RNA.
These data indicate that cell failure in polyQdiseasesmay be the
result of both an abnormal function of the protein harboring the
expanded glutamine and the altered properties of the expanded-
CAG RNA. The secondary structure of the CAG-repeat in each
gene context and the dynamic expression and activity of RBP may
provide speciﬁc pathogenic scenarios for cell dysfunction.
miRNAs PERTURBTIONS IN TREDs
MicroRNAs are small RNA molecules of 20–24 nucleotides that
generally inhibit the expression of target mRNA, by a mechanism
involving mRNA degradation, translational inhibition or a combi-
nation of the two (reviewed in Esteller, 2011). miRNAs biogenesis
involves processing of a primary transcript in the nucleus (pri-
miRNAs) by the Drosha/DGCR8 microprocessor. This generates
a precursor miRNA (pre-miRNA) that is exported to the cyto-
plasm by exoprtin-5, where the endonuclease Dicer cleaves it to
release the double-stranded miRNA. One of these strands pref-
erentially loads onto an RNA induced silencing complex (RISC),
while the other strand is usually degraded. In animals, miRNAs
recognize their targets through complementarity with the seed
sequence (nucleotides 2–8 of the 5′ end of the miRNA). Hundreds
of mRNA targets could exist per miRNA family and at least 30%
of the mRNAs are targeted by miRNAs (O’Carroll and Schaefer,
2013).
miRNAs are ﬁne-tuners of gene expression with key roles in
the central nervous system function and development. The ﬁrst
evidences for a major role of miRNAs in neurons involved in vitro
and in vivo models of loss of function of Dicer, a key limiting
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endonuclease in miRNA biogenesis. Dicer depletion disrupts the
development of the CNS, with clear effects on brain morphol-
ogy and cell-type speciﬁcation and differentiation. Conditional
knocking-down of Dicer in speciﬁc neuronal populations in adult
mice further suggests a role of miRNAs in postmitotic long-
term neuronal maintenance (Kim et al., 2007; Schaefer et al., 2007;
Haramati et al., 2010). Furthermore, conditional loss of Dicer in
astrocytes and oligodendrocyes causes neuronal dysfunction and
degeneration (Shin et al., 2009; Tao et al., 2011). DGCR8 is one
of the genes whose heterozygous deletion results in DiGeorge
syndrome (Shiohama et al., 2003) with the majority of patients
showing heart defects and developmental problems. The descrip-
tion of DGCR8 as key component of the microprocessor (Gregory
et al., 2004) highlighted that defects in miRNA biogenesis likely
underlie developmental defects. Haploinsufﬁciency of the micro-
processor member DGCR8 also compromises neuronal viability
in mice (Stark et al., 2008).
Perturbations of miRNA pathways have emerged as effectors
of CNS damage, contributing to impaired cell homeostasis and
neuronal death. MiRNAs deregulation produces alterations in
the transcriptome that impact brain function, with consequences
in neurodegeneration-relevant pathways, including inﬂammation,
oxidative stress and mitochondrial integrity. The causes of miRNA
expression deregulation are diverse, including changes in the activ-
ity of transcription factors or disease-associated genes and/or
alterations in miRNA biogenesis or stability (Packer et al., 2008;
Martí et al., 2010). Ischemia, excitotoxicity, oxidative stress or
aging are examples of harmful stimuli producing alterations in
the coding and non-coding transcriptome (Persengiev et al., 2011;
Xu et al., 2012).
Several studies point to an involvement of miRNAs in the
pathogenicity associated to TREDs. The toxicity of Ataxin-3 is
enhanceduponDicer ablation inDrosophila andhuman cellmod-
els. The administration of a pool of sRNAs restored Ataxin-3 toxic
effect, suggesting a protective role of miRNAs (Bilen et al., 2006).
Supporting a protective role of miRNAs in polyQ diseases, miR-
34b was shown to mitigate the toxicity of Ataxin-3 in a Drosophila
model (Liu et al., 2012).
The activity of disease-associated genes has emerged as one
of the causes for miRNA deregulation in TREDs. Mutant HTT
protein interacts with Ago2 in the P-bodies, and HTT deple-
tion impairs miRNA mediated gene silencing (Savas et al., 2008).
Strong miRNA deregulation has been detected in HD that may be
in part associated with altered activity of the RE1-silencing tran-
scription factor (REST). The expanded HTT polyQ track impedes
sequestration of REST by wild-type HTT in the cytoplasm, there-
fore allowing its translocation to the nucleus. Mislocalization in
the nucleus permits REST binding to RE1 repressor sequences
thus decreasing neuronal gene expression, which triggers neuronal
dysfunction. Several miRNAs with RE1 upstream binding sites
are down-regulated in HD, including miR-9/miR-9* (Packer et al.,
2008). A negative feed-back loop was proposed to occur in HD,
involving the activity of REST-silencing complex that is regulated
through the effect of miR9 and miR-9* on REST and Co-REST,
respectively (Packer et al., 2008). High-throughput sequencing
analysis has revealed strong miRNA expression deregulation in
the striatum and frontal cortex of patients with HD (Martí et al.,
2010). A signiﬁcant enrichment of down-regulated miRNAs har-
boring upstream RE1 or P53 binding sites was also reported in this
study, suggesting a major role of these transcriptional modulators
in miRNA deregulation.
In another example, Ataxin-2 has been recently identiﬁed
as a component of the miRNA pathway to regulate synapse-
speciﬁc long-term-plasticity. This targets the putative relevance
of ataxin-2/miRNAs in spinocerebellar ataxia neurodegeneration
(McCann et al., 2011).
Signiﬁcant miRNA deregulation has been also detected in
pre-symptomatic versus symptomatic SCA1 mouse model cere-
bellum, which suggests a role of miRNAs in the evolution of
the disease (Rodriguez-Lebron et al., 2013). In addition, the
miRNA transcriptome has been also characterized in the mus-
cle of a Drosophila model of DM1, expressing CTG repeats
alone (Fernandez-Costa et al., 2013). Among the downregulated
miRNAs, miR-1, miR-7, and miR-10 were conﬁrmed in muscle
of patients with DM1. Interestingly, over-expression of miR-10
extended the lifespan of CUG-expressing ﬂies, suggesting a role in
the disease.
Deregulation of miRNA speciﬁcally targeting dosage-sensitive
disease genesmayhighlight their relevance as pathogenic biomark-
ers, which could be selectively targeted in therapeutic strategies.
Dentatorubral-pallidoluysian atrophy (DRPLA) is caused by a
CAG/polyQ expansion in DRPLA gene/protein, respectively. miR-
200b and miR-429 target REPRE mRNA, whose protein product
binds to DRPLA protein. Overexpression of REPRE induces
DRPLA mislocalization. Thus, expression levels of miR-200b and
miR-429 could potentially contribute toDRPLA (Yanagisawa et al.,
2000; Karres et al., 2007). In another example, miR-886-3p targets
the frataxin gene (FXN) that carries an intronic GAA. TTC triplet
repeat expansion in Friedeich ataxia (FRDA; Mahishi et al., 2012).
FXN mRNA and protein are decreased in FRDA. The authors
found increased levels of miR-886-3p in blood and cells of patients
with FRDA and further demonstrated that inhibition of miR-886-
3p resulted in increases of FXN mRNA and protein. In addition,
miR-19, miR-101 and miR-130 regulate Ataxin 1 (ATXN1) that
causes spinocerebellar ataxia 1 (SCA1), when presenting a CAG
expansion (Lee et al., 2008). The authors showed that inhibition
of the activity of these miRNAs enhanced the cytotoxic activity
of ATXN1 with an expanded polyQ in human cells, suggesting a
miRNA mechanism modulating pathogenesis. More recently, it
has been shown that, miR-144 and miR-101 play a central role
in modulating the levels of ATXN1 (Persengiev et al., 2011). In
SCA1 patients and aging the levels of these miRNAs are increased,
suggesting a role in neurodegeneration. Finally, the 3′UTR of the
FMR1 mRNA is targeted by miR-101, miR-129-5p, and miR-221
(Zongaro et al., 2013). Downregulation of miRNAs has been gen-
erally detected in the brain of patients with FXTAs (Sellier et al.,
2013) and miR-221 is also downregulated in peripheral blood
of males with FXTAS (Alvarez-Mora et al., 2013). Thus, dereg-
ulation of certain miRNAs may contribute to upregulation of
expanded FMR1, which has been shown to participate in FXTAS
pathogenesis.
These data indicate that altered expression of speciﬁc miR-
NAs may contribute to TREDs pathogenesis, directly perturbing
the expression of dosage-sensitive genes that are essential in the
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maintenance of cell homeostasis. The dynamics of miRNA alter-
ations may deﬁne the relevance of miRNA-pathways in disease
evolution.
THERAPEUTIC APPROACHES TARGETTING RNA-TOXICICITY
Several therapeutic targets in polyQ diseases such as HD involve
the intervention of pathways perturbed by mutant polyQ proteins,
including histone acetylation, excitotoxicity and oxidative stress
(Clabough, 2013). Mutant HTT inhibits acetyltransferases, result-
ing in reduced levels of acetylated histones (Gray, 2010) Inhibition
of histone deacetylase activity (HDACs) has been proposed as
a therapeutic approach, alleviating altered gene expression pro-
duced by diminished acetyltransferase activity (Steffan et al.,
2001; Gray, 2010). In addition, mitochondrial impairment and
excitotoxicity have been involved in neuronal death in HD.
Administration of antioxidants such as Coenzyme Q10 slow stri-
atal atrophy in mouse models of HD (Beal, 2002) and delivery
of growth factors and cytokines modify neuronal degenera-
tion and prevents excitotoxic deﬁcits in murine HD models
(Mittoux et al., 2000; Perez-Navarro et al., 2000; de Almeida
et al., 2001). Other strategies involve lowering the amount of
mutant polyQ protein by reducing its production (see below)
or enhancing its clearance. In this line, increased mutant HTT
protein turnover in a mouse model improves disease outcome
(Southwell et al., 2009).
Although targeting the mutant/expanded polyQ protein or
its downstream pathogenic effectors improves disease readouts,
these strategies may not impede expanded TNR RNA toxicity.
Approaches aimed at blockingprotein and/orRNA toxicity include
the use of antisense oligonucleotides (ASOs) or RNAi (short hair-
pin RNAs, shRNA, double stranded siRNA or modiﬁed single
stranded siRNAs), targeting the expression of the mutant gene
(Sah and Aronin, 2011; Watts and Corey, 2012; Figure 4). RNAi
using shRNA againstmutant TREDs genemRNA and protein have
been successfully used in vivo. Intrastriatal adenoviral-delivery
shRNA targeting mutant human HTT resulted in improved neu-
ropathology and behavioral deﬁcits in HD mouse models (Harper
et al., 2005; Rodriguez-Lebron et al., 2005). Davidson’s lab later
showed that miRNA expression systems to inhibit HTT were
more efﬁcient, overcoming unspeciﬁc toxic effects induced by
shRNA expressing vectors (McBride et al., 2008; Boudreau et al.,
2011). The therapeutic potential of 2′-O-(2-methoxy)ethyl mod-
iﬁed ASOs targeting human HTT has been recently addressed
(Kordasiewicz et al., 2012). The intracerebral transient infusion
of these ASOs resulted in the RNAse H mediated degradation
of the human HTT mRNA, in transgenic mouse models of HD
(Kordasiewicz et al., 2012). Importantly, transient HTT reduc-
tion resulted in sustained motor and histopathological phenotypic
reversal in the HD rodent models.
Because multiple studies suggest that reducing the expression
of the wild-type allele may have deleterious consequences, selec-
tive targeting of the expanded allele should be optimal (Omi
et al., 2005; Godin et al., 2010; Huang et al., 2011). In polyQ dis-
eases, single-nucleotide polymorphisms (SNPs) linked to repeat
expansions that distinguish wild-type from mutant alleles offer
possibilities for speciﬁc targeting by RNAi. SNP targeting has been
shown in HD (Schwarz et al., 2006; Carroll et al., 2011), SCA3 (Li
et al., 2004) and SCA7 (Scholeﬁeld et al., 2009). Low frequency
of allele-distinguishing SNPs in the human population limits this
strategy. However, several authors have shown that targeting sev-
eral speciﬁc SNPs can be applied to the majority of HD patients
(Lombardi et al., 2009; Pﬁster et al., 2009; Warby et al., 2009).
Other potential therapeutic strategies in polyQ diseases, are
based on the use of several types of modiﬁed single strandedASOs
that target the CAG expansion in the mutant HTT or ATXN3
mRNA,while preserving thenormal functionof thewild type allele
(Hu et al., 2009a,b,c; Gagnon et al., 2010; Fiszer et al., 2012; Yu
et al., 2012). The longer CAG track in the mutant allele offers more
binding sites for the complementary ASOs (Figure 4). In addition,
the RNA structures of the expanded CAG that differ from those of
the wild type allele (de Mezer et al., 2011; Krzyzosiak et al., 2012),
may offer distinctive feature for preferential recognition of the
mutant allele. In these studies, single-stranded ASOs containing
locked nucleic acid (LNA) or peptide nucleic acid have been shown
to selectively block the expression of mutant HTT at the protein
level. This effect was not associated with extensive HTT mRNA
degradation and LNA ASOs were shown to form stable structures
with the target RNA. Although expanded RNA toxicity in HD
has not been addressed, the formation of stable LNA ASOs : RNA
duplexes has also the potential to block expandedCAG toxic effects
in HTT mRNA.
Several studies have demonstrated a similar therapeutic poten-
tial of a CAG-repeat antisense or morpholino targeted to
expanded-CUG in the DMPK mRNA (Mulders et al., 2009). In
cell myoblast-myotube and patient cell models a 2′-O-methyl-
phosphorothioate-modiﬁed (CAG)7ASO silenced DMPK expres-
sion and reduced the ribonuclear aggregates. Intramuscular
administration of these ASO in a DM1 mouse model further
reduced expanded RNA toxicity (Mulders et al., 2009). In another
study, a morpholino anti-sense (CAG)25 was shown to block the
interaction of MBNL1 with the expansion in a mouse model,
further dispersing nuclear RNA foci, preventing alterations in
alternative splicing and preventing RNA toxicity. More recently,
it has been shown that systemic administration of ASOs effec-
tively knockeddown the expression of nuclear retained-transcripts
containing expanded CUG in the muscle, thus correcting the
physiological, histopathological and transcriptional alterations
associated to this DM1 model (Wheeler et al., 2012).
Together, these data suggest that inTREDs, targeting the expres-
sion and activity of the expanded allele both at the RNA and
protein levels is a promising therapeutic strategy.
CONCLUSION
RNA toxicity is a process underlying pathogenicity in TREDs,
with TNR expansions occurring in both coding and non-coding
regions of speciﬁc genes. Sequestration of transcriptionally active
RBP, and RBP participating in miRNA biogenesis result in direct
and indirect perturbations of the coding-transcriptome, which
likely contribute to cell dysfunction. Full characterization of the
repertoire of RBP in different types of TNR expansions is essen-
tial to understand common detrimental pathways in etiologically
diverse neurological disorders. Studies that take into consideration
the gene context may provide hints to understand disease speciﬁc
aspects.
Frontiers in Molecular Neuroscience www.frontiersin.org December 2013 | Volume 6 | Article 45 | 10
“fnmol-06-00045” — 2013/12/2 — 10:36 — page 11 — #11
Martí and Estivill RNA toxicity in TREDs
FIGURE 4 | Selective targeting of the expanded allele inTREDs. shRNA,
modiﬁed ASO or siRNA directed against the expanded allele results in
degradation of mutant mRNA or blockage of the mutant protein synthesis,
which impedes the detrimental activities of the expandedTNR in the mRNA
and the mutant protein. With this strategy the normal allele is not targeted,
allowing its function.
The biogenesis and activity of sCNG may contribute to TREDs
pathogenesis. The gene silencing activity of these species likely trig-
ger downstream detrimental effects, which may differ, depending
on the cell type. This mechanism may complement the damag-
ing activity of expanded protein and/or expanded RNA. Whether
sCNG mechanisms are only related with gene silencing or present
other activities and the real importance of sCNG mechanisms in
each TRED remain to be determined.
In each TRED, the mechanistic bases for tissue speciﬁcity,
with particular affectation of selective neuronal types, remain
largely unknown. The different RNA-based pathogenic pro-
cesses provide a number of scenarios that may underlie this
speciﬁcity. These include the dynamic expression and cellular
and subcellular localization of RBP, the amount of expression
of the sense and anti-sense transcripts spanning the expanded
TNR in each cell context, the regulation of the biogenesis and
activity of sCNG in different brain areas and/or the temporal
and spatial primary and secondary perturbations of the miRNA
transcriptome.
Themechanistic complexity inTREDs stresses theneedof addi-
tional studies to dissect the relative relevance of expanded protein-
RNA-, and/or sRNAs-mechanisms in each disease. In this con-
text, the use of modiﬁed ASOs or siRNA directed to the expanded
TNR has the potential to block deleterious effects of expanded
full-length RNA and derived sCNG, with concomitant inhibition
of expanded protein expression.
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